Stocks
Bolt Biotherapeutics, Inc.BOLT
NASDAQHealthcareBiotechnology$6.27
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for solid tumors, with its lead candidate BDC-1001 in Phase 2 trials for HER2-positive cancers. Investors track the stock for its proprietary Bolide platform, which aims to improve ADC tolerability and efficacy, and for potential partnership or licensing deals in the oncology space.
52W Range: $3.10-$7.78
Congressional Interest in Bolt Biotherapeutics, Inc. (BOLT)
No congressional trades have been disclosed for Bolt Biotherapeutics, Inc. (BOLT) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading BOLT?
No congressional trades found for this stock.